ATE309250T1 - Modulatoren der protein tyrosin phosphatase (ptpases) - Google Patents

Modulatoren der protein tyrosin phosphatase (ptpases)

Info

Publication number: ATE309250T1
Authority: AT; Austria
Prior art keywords: sub; ptpases; protein tyrosine; modulators; compounds
Prior art date: 1999-09-10

Application number

AT00958277T

Other languages

English (en)

Inventor

Henrik Sune Andersen

Thomas Kruse Hansen

Jesper Lau

Yu Ge

Daniel Dale Holsworth

Todd Kevin Jones

Luke Milburn Judge

Wiliam Charles Ripka

Barry Zvi Shapira

Roy Teruyuki Uyeda

Original Assignee

Novo Nordisk As

Ontogen Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-10

Filing date

2000-09-11

Publication date

2005-11-15

2000-09-11 Application filed by Novo Nordisk As, Ontogen Corp filed Critical Novo Nordisk As

2005-11-15 Application granted granted Critical

2005-11-15 Publication of ATE309250T1 publication Critical patent/ATE309250T1/de

Links

102000002727 Protein Tyrosine Phosphatase Human genes 0.000 title abstract 3
108020000494 protein-tyrosine phosphatase Proteins 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
208000002705 Glucose Intolerance Diseases 0.000 abstract 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 1
101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
-1 PTPalpha Proteins 0.000 abstract 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 1
102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 abstract 1
101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
201000009104 prediabetes syndrome Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Obesity (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Electrodes Of Semiconductors (AREA)
Enzymes And Modification Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT00958277T 1999-09-10 2000-09-11 Modulatoren der protein tyrosin phosphatase (ptpases) ATE309250T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA199901278		1999-09-10
PCT/DK2000/000503 WO2001019831A1 (en)	1999-09-10	2000-09-11	MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)

Publications (1)

Publication Number	Publication Date
ATE309250T1 true ATE309250T1 (de)	2005-11-15

Family

ID=8103050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00958277T ATE309250T1 (de)	1999-09-10	2000-09-11	Modulatoren der protein tyrosin phosphatase (ptpases)

Country Status (7)

Country	Link
US (1)	US7019026B1 (de)
EP (1)	EP1214325B1 (de)
JP (1)	JP2003509430A (de)
AT (1)	ATE309250T1 (de)
AU (1)	AU6985300A (de)
DE (1)	DE60023923D1 (de)
WO (1)	WO2001019831A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1214060A2 (de) *	1999-09-10	2002-06-19	Novo Nordisk A/S	Verfahren zur hemmung von tyrosinphophatase 1b und/oder t-zellenprotein-tyronsinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 4
MXPA02012605A (es)	2000-06-28	2003-05-14	Squibb Bristol Myers Co	Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
US7001911B2 (en)	2000-06-28	2006-02-21	Bristol-Myers Squibb Company	Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en)	2001-06-20	2004-04-22	Salvati Mark E.	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
ATE321052T1 (de) *	2000-07-07	2006-04-15	Novo Nordisk As	Modulatoren von protein tyrosin phosphatasen (ptpasen)
US6613903B2 (en)	2000-07-07	2003-09-02	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (PTPases)
US6972340B2 (en)	2000-08-29	2005-12-06	Abbott Laboratories	Selective protein tyrosine phosphatatase inhibitors
US6953679B2 (en)	2000-09-19	2005-10-11	Bristol-Myers Squibb Company	Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
WO2002024702A1 (en) *	2000-09-19	2002-03-28	Bristol-Myers Squibb Company	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002100397A1 (en) *	2001-06-07	2002-12-19	Wyeth	COMBINATION OF A PTPase INHIBITOR AND AN ANTILIPEMIC AGENT
US7291639B2 (en) *	2001-06-20	2007-11-06	Wyeth	Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7087636B2 (en)	2001-12-19	2006-08-08	Bristol-Myers Squibb Company	Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
KR100868587B1 (ko)	2002-04-03	2008-11-12	노파르티스 아게	Ｐｔｐａｓｅ 1ｂ 억제제로서의 5-치환된1,1-디옥소-1,2,5-티아졸리딘-3-온 유도체
AU2007229370B2 (en) *	2002-04-03	2010-06-17	Novartis Ag	5-substituted 1,1-dioxo-1,2,5-thiazolidine-3-one derivatives as PTPase 1B inhibitors
US7169797B2 (en)	2003-02-14	2007-01-30	Abbott Laboratories	Protein-tyrosine phosphatase inhibitors and uses thereof
WO2005023818A2 (en) *	2003-09-10	2005-03-17	Gpc Biotech Ag	Heterobicyclic compounds as pharmaceutically active agents
US7141596B2 (en)	2003-10-08	2006-11-28	Incyte Corporation	Inhibitors of proteins that bind phosphorylated molecules
WO2005081954A2 (en)	2004-02-25	2005-09-09	Wyeth	Inhibitors of protein tyrosine phosphatase 1b
SE0500055D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 3
CN101163690A (zh) *	2005-04-20	2008-04-16	默克公司	苯并噻吩异羟肟酸衍生物
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009032321A2 (en)	2007-09-06	2009-03-12	Genaera Corporation	A method for treating diabetes
BRPI0917540A2 (pt)	2008-08-05	2015-11-17	Daiichi Sankyo Co Ltd	composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
SG10201510665WA (en)	2009-12-04	2016-01-28	Sunovion Pharmaceuticals Inc	Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2608474T3 (es)	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en)	2011-03-08	2014-11-25	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
CN102199157B (zh) *	2011-03-17	2013-04-17	鲁东大学	一种含溴的苯并吡喃类化合物及其制备和应用
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX367255B (es)	2012-04-20	2019-08-12	Ohr Pharmaceutical Inc	Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
ES2885181T3 (es)	2014-04-15	2021-12-13	Vertex Pharma	Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
MY176508A (en) *	2014-04-28	2020-08-12	Jiangsu Kanion Parmaceutical Co Ltd	Anti-enterovirus 71 thiadiazolidine derivative
CN107325075B (zh) *	2016-04-29	2020-07-28	正大天晴药业集团股份有限公司	一种泊马度胺的制备方法
MA45795A (fr)	2016-07-29	2019-06-05	Sunovion Pharmaceuticals Inc	Composés et compositions, et utilisations associées
PT3494119T (pt)	2016-07-29	2024-12-10	Pgi Drug Discovery Llc	Compostos e composições e seus usos
MX390141B (es)	2017-02-16	2025-03-20	Sunovion Pharmaceuticals Inc	Metodos para tratar esquizofrenia
CA3070993C (en)	2017-08-02	2025-05-20	Sunovion Pharmaceuticals Inc.	ISOCHROMANE COMPOUNDS AND THEIR USES
UA130249C2 (uk)	2018-02-16	2025-12-31	Сумітомо Фарма Америка, Інк.	Солі, кристалічні форми і способи їх отримання
EP3938045A1 (de)	2019-03-14	2022-01-19	Sunovion Pharmaceuticals Inc.	Salze einer isochromanylverbindung und kristalline formen, verfahren zur herstellung, therapeutische verwendungen und pharmazeutische zusammensetzungen davon
CN110054993B (zh) *	2019-04-04	2021-02-26	筑迹(深圳)创新健康科技有限公司	一种长寿命有机硅聚合物抗菌液及其制备方法、抗菌涂层的制备方法
CA3180115A1 (en)	2020-04-14	2021-10-21	Sunovion Pharmaceuticals Inc.	(s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3953468A (en)	1974-03-15	1976-04-27	The Upjohn Company	3-Cyano thiophen-2-yl oxamic acid and derivatives
GB1583679A (en)	1977-10-11	1981-01-28	Bristol Myers Co	Thieno (2,3-d) pyrimidine and other thiophene-derived anti-allergic agents
US6262044B1 (en) *	1998-03-12	2001-07-17	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (PTPASES)
WO1999046267A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
WO1999046237A1 (en) *	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases
EP1062218A1 (de) *	1998-03-12	2000-12-27	Novo Nordisk A/S	Modulatoren der protein-tyrosin-phosphatasen (ptphasen)

2000
- 2000-09-11 AT AT00958277T patent/ATE309250T1/de not_active IP Right Cessation
- 2000-09-11 EP EP00958277A patent/EP1214325B1/de not_active Expired - Lifetime
- 2000-09-11 US US09/662,457 patent/US7019026B1/en not_active Expired - Fee Related
- 2000-09-11 DE DE60023923T patent/DE60023923D1/de not_active Expired - Lifetime
- 2000-09-11 JP JP2001523408A patent/JP2003509430A/ja active Pending
- 2000-09-11 AU AU69853/00A patent/AU6985300A/en not_active Abandoned
- 2000-09-11 WO PCT/DK2000/000503 patent/WO2001019831A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP1214325A1 (de)	2002-06-19
DE60023923D1 (de)	2005-12-15
WO2001019831A1 (en)	2001-03-22
AU6985300A (en)	2001-04-17
JP2003509430A (ja)	2003-03-11
EP1214325B1 (de)	2005-11-09
US7019026B1 (en)	2006-03-28

Legal Events

Date	Code	Title	Description
2006-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60023923D1 (de)	2005-12-15	Modulatoren der protein tyrosin phosphatase (ptpases)
ATE329920T1 (de)	2006-07-15	Modulatoren der protein tyrosin phosphatase (ptpases)
ATE321052T1 (de)	2006-04-15	Modulatoren von protein tyrosin phosphatasen (ptpasen)
DE69910045D1 (de)	2003-09-04	Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
ATE308546T1 (de)	2005-11-15	Modulatoren der protein tyrosin phosphatase (ptpases)
BR0109062A (pt)	2002-11-26	Inibidores de frutose-1,6-bisfosfatase de arila
ATE396993T1 (de)	2008-06-15	Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
NO20043259L (no)	2004-09-16	Bindingsproteiner som biosensorer
EP1644514A4 (de)	2009-05-27	Temperaturstabile amylase-polypeptide, für diese polypeptide codierende nukleinsäuren und verwendungen davon
TR199900920T2 (xx)	1999-06-21	Nafthiridin t�revleri.
PT914299E (pt)	2002-12-31	Composicoes de vidro silico-sodo-calcicas e suas aplicacoes
DK0833839T3 (da)	2003-04-14	Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
DK1070056T3 (da)	2004-11-08	Phthalazinon-PDE III/IV-inhibitorer
AU8023898A (en)	1998-12-30	Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy
ATE355284T1 (de)	2006-03-15	Inhibitoren von serinproteasen
PT1149092E (pt)	2004-03-31	4- e 5-alciniloxindois e 4- e 5-alceniloxindois
PT1267869E (pt)	2004-10-29	Antogonistas de receptor de glutamato metabotropico para o tratamento de tolerancia e de dependencia
BR0316324A (pt)	2005-09-27	Polipeptìdeos e conjugados de interferon-alfa
DE60103856D1 (de)	2004-07-22	Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
SE0003476D0 (sv)	2000-09-28	Compounds
ATE290857T1 (de)	2005-04-15	Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
SE9903290D0 (sv)	1999-09-15	Novel compounds
DE60202669D1 (de)	2005-02-24	6-phenylbenzonaphthyidine
ATE307494T1 (de)	2005-11-15	Zusammensetzung, welche pektinmethylesterase und zwei substrate beinhaltet
PT1244614E (pt)	2004-10-29	Inibidores de triptase